Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

摘要: Considerable progress has been made in the treatment of multiple myeloma past decade with median survival for disease improving significantly. This come through a combination better understanding biology and coordinated research into new approaches including supportive care. However, patients eventually become refractory to available treatments succumb disease, highlighting need develop approaches. The genetic heterogeneity clonal evolution under pressure underlie development resistance, underscoring more effective therapies that can eradicate at initial as well classes drugs varying mechanisms action. To this end, there intense focus on exploring novel therapy small-molecule inhibitors targeting specific abnormalities, immune monoclonal antibodies adaptive T-cell therapy, epigenetic Although many these are early stages clinical development, data appear be very promising. Many safely effectively combined current such proteasome immunomodulatory drugs, further enhancing options myeloma.